CDH2 and neoplasm: Treatment with epidoxorubicin alone produced >82% tumor regression within 4 weeks (Figure 6B), but significantly increased the percentage of N-cad+ cells, accompanied by reduced quantity of E-cad+ cells, in residual lesions (Figure 6D).